Adenoviral vector-mediated gene therapy for gliomas: coming of age

Autores
Castro, María G.; Candolfi, Marianela; Wilson, Thomas J.; Calinescu, Alexandra; Paran, Christopher; Kamran, Neha; Koschmann, Carl; Moreno Ayala, Mariela Alejandra; Assi, Hikmat; Lowenstein, Pedro R.
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
INTRODUCTION: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and it carries a dismal prognosis. Adenoviral vector (Ad)-mediated gene transfer is being developed as a promising therapeutic strategy for GBM. Preclinical studies have demonstrated safety and efficacy of adenovirus administration into the brain and tumor mass in rodents and into the non-human primates' brain. Importantly, Ads have been safely administered within the tumor resection cavity in humans. AREAS COVERED: This review gives background on GBM and Ads; we describe gene therapy strategies for GBM and discuss the value of combination approaches. Finally, we discuss the results of the human clinical trials for GBM that have used Ads. EXPERT OPINION: The transduction characteristics of Ads, and their safety profile, added to their capacity to achieve high levels of transgene expression have made them powerful vectors for the treatment of GBM. Recent gene therapy successes in the treatment of retinal diseases and systemic brain metabolic diseases encourage the development of gene therapy for malignant glioma. Exciting clinical trials are currently recruiting patients; although, it is the large randomized Phase III controlled clinical trials that will provide the final decision on the success of gene therapy for the treatment of GBM.
Fil: Castro, María G.. University of Michigan; Estados Unidos
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Wilson, Thomas J.. University of Michigan; Estados Unidos
Fil: Calinescu, Alexandra. University of Michigan; Estados Unidos
Fil: Paran, Christopher. University of Michigan; Estados Unidos
Fil: Kamran, Neha. University of Michigan; Estados Unidos
Fil: Koschmann, Carl. University of Michigan; Estados Unidos
Fil: Moreno Ayala, Mariela Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Assi, Hikmat. University Of Michigan Medical School;
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
Materia
DENDRITIC CELLS
FMS-LIKE TYROSINE KINASE 3 LIGAND
GLIOBLASTOMA MULTIFORME
HIGH CAPACITY ADENOVIRUS
HSV1-TK
IMMUNOTHERAPY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/15324
Acceder
id CONICETDig_ea5e387317604a90ce1dbb8f3c8838a8
oai_identifier_str oai:ri.conicet.gov.ar:11336/15324
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Adenoviral vector-mediated gene therapy for gliomas: coming of ageCastro, María G.Candolfi, MarianelaWilson, Thomas J.Calinescu, AlexandraParan, ChristopherKamran, NehaKoschmann, CarlMoreno Ayala, Mariela AlejandraAssi, HikmatLowenstein, Pedro R.DENDRITIC CELLSFMS-LIKE TYROSINE KINASE 3 LIGANDGLIOBLASTOMA MULTIFORMEHIGH CAPACITY ADENOVIRUSHSV1-TKIMMUNOTHERAPYhttps://purl.org/becyt/ford/3.4https://purl.org/becyt/ford/3INTRODUCTION: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and it carries a dismal prognosis. Adenoviral vector (Ad)-mediated gene transfer is being developed as a promising therapeutic strategy for GBM. Preclinical studies have demonstrated safety and efficacy of adenovirus administration into the brain and tumor mass in rodents and into the non-human primates' brain. Importantly, Ads have been safely administered within the tumor resection cavity in humans. AREAS COVERED: This review gives background on GBM and Ads; we describe gene therapy strategies for GBM and discuss the value of combination approaches. Finally, we discuss the results of the human clinical trials for GBM that have used Ads. EXPERT OPINION: The transduction characteristics of Ads, and their safety profile, added to their capacity to achieve high levels of transgene expression have made them powerful vectors for the treatment of GBM. Recent gene therapy successes in the treatment of retinal diseases and systemic brain metabolic diseases encourage the development of gene therapy for malignant glioma. Exciting clinical trials are currently recruiting patients; although, it is the large randomized Phase III controlled clinical trials that will provide the final decision on the success of gene therapy for the treatment of GBM.Fil: Castro, María G.. University of Michigan; Estados UnidosFil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; ArgentinaFil: Wilson, Thomas J.. University of Michigan; Estados UnidosFil: Calinescu, Alexandra. University of Michigan; Estados UnidosFil: Paran, Christopher. University of Michigan; Estados UnidosFil: Kamran, Neha. University of Michigan; Estados UnidosFil: Koschmann, Carl. University of Michigan; Estados UnidosFil: Moreno Ayala, Mariela Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; ArgentinaFil: Assi, Hikmat. University Of Michigan Medical School;Fil: Lowenstein, Pedro R.. University of Michigan; Estados UnidosTaylor & Francis2014-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/15324Castro, María G.; Candolfi, Marianela; Wilson, Thomas J.; Calinescu, Alexandra; Paran, Christopher; et al.; Adenoviral vector-mediated gene therapy for gliomas: coming of age; Taylor & Francis; Expert Opinion On Biological Therapy; 14; 9; 9-2014; 1241-12571471-2598enginfo:eu-repo/semantics/altIdentifier/doi/10.1517/14712598.2014.915307info:eu-repo/semantics/altIdentifier/url/http://www.tandfonline.com/doi/full/10.1517/14712598.2014.915307info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:44:18Zoai:ri.conicet.gov.ar:11336/15324instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:44:18.367CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Adenoviral vector-mediated gene therapy for gliomas: coming of age
title Adenoviral vector-mediated gene therapy for gliomas: coming of age
spellingShingle Adenoviral vector-mediated gene therapy for gliomas: coming of age
Castro, María G.
DENDRITIC CELLS
FMS-LIKE TYROSINE KINASE 3 LIGAND
GLIOBLASTOMA MULTIFORME
HIGH CAPACITY ADENOVIRUS
HSV1-TK
IMMUNOTHERAPY
title_short Adenoviral vector-mediated gene therapy for gliomas: coming of age
title_full Adenoviral vector-mediated gene therapy for gliomas: coming of age
title_fullStr Adenoviral vector-mediated gene therapy for gliomas: coming of age
title_full_unstemmed Adenoviral vector-mediated gene therapy for gliomas: coming of age
title_sort Adenoviral vector-mediated gene therapy for gliomas: coming of age
dc.creator.none.fl_str_mv Castro, María G.
Candolfi, Marianela
Wilson, Thomas J.
Calinescu, Alexandra
Paran, Christopher
Kamran, Neha
Koschmann, Carl
Moreno Ayala, Mariela Alejandra
Assi, Hikmat
Lowenstein, Pedro R.
author Castro, María G.
author_facet Castro, María G.
Candolfi, Marianela
Wilson, Thomas J.
Calinescu, Alexandra
Paran, Christopher
Kamran, Neha
Koschmann, Carl
Moreno Ayala, Mariela Alejandra
Assi, Hikmat
Lowenstein, Pedro R.
author_role author
author2 Candolfi, Marianela
Wilson, Thomas J.
Calinescu, Alexandra
Paran, Christopher
Kamran, Neha
Koschmann, Carl
Moreno Ayala, Mariela Alejandra
Assi, Hikmat
Lowenstein, Pedro R.
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv DENDRITIC CELLS
FMS-LIKE TYROSINE KINASE 3 LIGAND
GLIOBLASTOMA MULTIFORME
HIGH CAPACITY ADENOVIRUS
HSV1-TK
IMMUNOTHERAPY
topic DENDRITIC CELLS
FMS-LIKE TYROSINE KINASE 3 LIGAND
GLIOBLASTOMA MULTIFORME
HIGH CAPACITY ADENOVIRUS
HSV1-TK
IMMUNOTHERAPY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.4
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv INTRODUCTION: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and it carries a dismal prognosis. Adenoviral vector (Ad)-mediated gene transfer is being developed as a promising therapeutic strategy for GBM. Preclinical studies have demonstrated safety and efficacy of adenovirus administration into the brain and tumor mass in rodents and into the non-human primates' brain. Importantly, Ads have been safely administered within the tumor resection cavity in humans. AREAS COVERED: This review gives background on GBM and Ads; we describe gene therapy strategies for GBM and discuss the value of combination approaches. Finally, we discuss the results of the human clinical trials for GBM that have used Ads. EXPERT OPINION: The transduction characteristics of Ads, and their safety profile, added to their capacity to achieve high levels of transgene expression have made them powerful vectors for the treatment of GBM. Recent gene therapy successes in the treatment of retinal diseases and systemic brain metabolic diseases encourage the development of gene therapy for malignant glioma. Exciting clinical trials are currently recruiting patients; although, it is the large randomized Phase III controlled clinical trials that will provide the final decision on the success of gene therapy for the treatment of GBM.
Fil: Castro, María G.. University of Michigan; Estados Unidos
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Wilson, Thomas J.. University of Michigan; Estados Unidos
Fil: Calinescu, Alexandra. University of Michigan; Estados Unidos
Fil: Paran, Christopher. University of Michigan; Estados Unidos
Fil: Kamran, Neha. University of Michigan; Estados Unidos
Fil: Koschmann, Carl. University of Michigan; Estados Unidos
Fil: Moreno Ayala, Mariela Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Assi, Hikmat. University Of Michigan Medical School;
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
description INTRODUCTION: Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults and it carries a dismal prognosis. Adenoviral vector (Ad)-mediated gene transfer is being developed as a promising therapeutic strategy for GBM. Preclinical studies have demonstrated safety and efficacy of adenovirus administration into the brain and tumor mass in rodents and into the non-human primates' brain. Importantly, Ads have been safely administered within the tumor resection cavity in humans. AREAS COVERED: This review gives background on GBM and Ads; we describe gene therapy strategies for GBM and discuss the value of combination approaches. Finally, we discuss the results of the human clinical trials for GBM that have used Ads. EXPERT OPINION: The transduction characteristics of Ads, and their safety profile, added to their capacity to achieve high levels of transgene expression have made them powerful vectors for the treatment of GBM. Recent gene therapy successes in the treatment of retinal diseases and systemic brain metabolic diseases encourage the development of gene therapy for malignant glioma. Exciting clinical trials are currently recruiting patients; although, it is the large randomized Phase III controlled clinical trials that will provide the final decision on the success of gene therapy for the treatment of GBM.
publishDate 2014
dc.date.none.fl_str_mv 2014-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/15324
Castro, María G.; Candolfi, Marianela; Wilson, Thomas J.; Calinescu, Alexandra; Paran, Christopher; et al.; Adenoviral vector-mediated gene therapy for gliomas: coming of age; Taylor & Francis; Expert Opinion On Biological Therapy; 14; 9; 9-2014; 1241-1257
1471-2598
url http://hdl.handle.net/11336/15324
identifier_str_mv Castro, María G.; Candolfi, Marianela; Wilson, Thomas J.; Calinescu, Alexandra; Paran, Christopher; et al.; Adenoviral vector-mediated gene therapy for gliomas: coming of age; Taylor & Francis; Expert Opinion On Biological Therapy; 14; 9; 9-2014; 1241-1257
1471-2598
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1517/14712598.2014.915307
info:eu-repo/semantics/altIdentifier/url/http://www.tandfonline.com/doi/full/10.1517/14712598.2014.915307
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614480233758720
score 13.070432

Publicaciones similares